Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1542e8802a0e6a7a8a7c6bd5627eb857 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
filingDate |
2003-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2007-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21df534a441bc2a859b9c4090eae0a3d |
publicationDate |
2007-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-7193035-B2 |
titleOfInvention |
Crystals of insulin analogs and processes for their preparation |
abstract |
The invention relates to crystals of an insulin analog in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring neutral or acidic amino acid residue, where phenylalanine (Phe) in position B1 of the B chain can optionally be absent, the crystals being present in the space group R3 (No. 146) with the cell axes A=81.5 ű1 Å and C=33.3 ű1 Å, their preparation and use, and a pharmaceutical composition comprising these crystals. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9458219-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11261228-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016032869-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009067636-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013086927-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2930182-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10124040-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015084694-A2 |
priorityDate |
2002-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |